• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2019 年 9 月至 10 月，希腊爆发了产 KPC-2 的肺炎克雷伯菌，该菌对头孢他啶-阿维巴坦具有耐药性，是通过 VEB-1 突变体（VEB-25）介导的。

Outbreak of KPC-2-producing endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019.

机构信息

Infectious Diseases Laboratory, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

1st Internal Medicine & Infectious Diseases Department, Hygeia General Hospital, Athens, Greece.

出版信息

Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000028.

DOI:10.2807/1560-7917.ES.2020.25.3.2000028
PMID:31992391
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6988274/
Abstract

From September to October 2019, seven patients colonised or infected with a ceftazidime-avibactam (CZA)-resistant carbapenemase (KPC)-2-producing were detected in two intensive care units of a Greek general hospital. The outbreak strain was sequence type (ST)147 and co-produced KPC-2 and the novel plasmid-borne Vietnamese extended-spectrum β-lactamase (VEB)-25 harbouring a K234R substitution associated with CZA resistance. Epidemiological investigations revealed that the resistance was probably acquired by horizontal transmission independently from previous CZA exposure.

摘要

2019 年 9 月至 10 月，在希腊一家综合医院的两个重症监护病房中，检测到 7 例定植或感染产头孢他啶-阿维巴坦（CZA）耐药碳青霉烯酶（KPC）-2 的患者。暴发菌株为序列型（ST）147，同时产生 KPC-2 和新型质粒介导的越南超广谱β-内酰胺酶（VEB）-25，该酶携带与 CZA 耐药相关的 K234R 取代。流行病学调查显示，耐药性可能是通过水平传播获得的，与之前的 CZA 暴露无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ca6/6988274/f4d099e271c2/2000028-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ca6/6988274/f4d099e271c2/2000028-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ca6/6988274/f4d099e271c2/2000028-f1.jpg

相似文献

1
Outbreak of KPC-2-producing endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019.2019 年 9 月至 10 月，希腊爆发了产 KPC-2 的肺炎克雷伯菌，该菌对头孢他啶-阿维巴坦具有耐药性，是通过 VEB-1 突变体（VEB-25）介导的。
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000028.
2
Detection in two hospitals of transferable ceftazidime-avibactam resistance in due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019.2019 年，希腊两家医院检测到一种新型 VEB 酶变体导致的可转移头孢他啶-阿维巴坦耐药，其具有 Lys234Arg 取代，该酶变体与β-内酰胺酶有关。
Euro Surveill. 2020 Jan;25(2). doi: 10.2807/1560-7917.ES.2020.25.2.1900766.
3
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
4
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
5
A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated .一项大规模监测显示，KPC变体在临床分离菌株中介导对头孢他啶-阿维巴坦的耐药性。
Microbiol Spectr. 2024 Aug 6;12(8):e0025824. doi: 10.1128/spectrum.00258-24. Epub 2024 Jul 3.
6
A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.一株新型 KPC-166 型产头孢他啶/阿维巴坦酶耐药 ST307 肺炎克雷伯菌导致意大利重症监护 COVID 病房爆发。
J Microbiol Immunol Infect. 2024 Jun;57(3):457-469. doi: 10.1016/j.jmii.2024.03.004. Epub 2024 Mar 29.
7
Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.在由产肺炎克雷伯菌碳青霉烯酶（KPC）的肺炎克雷伯菌引起的多克隆暴发中，解读对新型碳青霉烯类β-内酰胺酶抑制剂联合制剂的可变耐药性，该肺炎克雷伯菌对头孢他啶/阿维巴坦耐药。
Clin Microbiol Infect. 2023 Apr;29(4):537.e1-537.e8. doi: 10.1016/j.cmi.2022.11.011. Epub 2022 Nov 19.
8
Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible ST11 is related to low mutation rates.产碳青霉烯酶肺炎克雷伯菌 ST11 对头孢他啶-阿维巴坦耐药/美罗培南敏感的 KPC-114 向 KPC-2 的回复与低突变率有关。
Microbiol Spectr. 2024 Oct 3;12(10):e0117324. doi: 10.1128/spectrum.01173-24. Epub 2024 Aug 27.
9
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
10
Emergence of ceftazidime-avibactam resistance in bla-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.产碳青霉烯酶肺炎克雷伯菌中 bla harbouring ST11 儿科患者出现头孢他啶-阿维巴坦耐药性。
Int J Antimicrob Agents. 2024 Jun;63(6):107163. doi: 10.1016/j.ijantimicag.2024.107163. Epub 2024 Apr 1.

引用本文的文献

1
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.突破耐药性：新型β-内酰胺酶抑制剂（阿维巴坦、瓦博巴坦、瑞来巴坦）抗多重耐药超级细菌的比较综述
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
2
Outbreak of High-Risk Clone ST323 Resistant to Ceftazidime-Avibactam Due to Acquisition of and to Cefiderocol Due to Mutated Gene.因获得blaOXA-181基因而对头孢他啶-阿维巴坦耐药且因mcr-1基因变异而对头孢地尔耐药的高危克隆ST323暴发。
Antibiotics (Basel). 2025 Feb 21;14(3):223. doi: 10.3390/antibiotics14030223.
3

本文引用的文献

1
Detection in two hospitals of transferable ceftazidime-avibactam resistance in due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019.2019 年，希腊两家医院检测到一种新型 VEB 酶变体导致的可转移头孢他啶-阿维巴坦耐药，其具有 Lys234Arg 取代，该酶变体与β-内酰胺酶有关。
Euro Surveill. 2020 Jan;25(2). doi: 10.2807/1560-7917.ES.2020.25.2.1900766.
2
Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.评价头孢他啶-阿维巴坦与美罗培南、阿米卡星、氨曲南、黏菌素或磷霉素联合使用对经过充分特征鉴定的多药耐药肺炎克雷伯菌和铜绿假单胞菌的协同作用。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00779-19. Print 2019 Aug.
3
Overexpression of caused by tandem amplification contributed to ceftazidime/avibactam resistance in hypervirulent and carbapenem-resistant .
串联扩增导致的过表达有助于产超广谱β-内酰胺酶和耐碳青霉烯的 对头孢他啶/阿维巴坦的耐药性。
Emerg Microbes Infect. 2024 Dec;13(1):2426481. doi: 10.1080/22221751.2024.2426481. Epub 2024 Nov 14.
4
sRNA expression profile of KPC-2-producing carbapenem-resistant Klebsiella pneumoniae: Functional role of sRNA51.产 KPC-2 碳青霉烯类耐药肺炎克雷伯菌的 sRNA 表达谱：sRNA51 的功能作用
PLoS Pathog. 2024 May 8;20(5):e1012187. doi: 10.1371/journal.ppat.1012187. eCollection 2024 May.
5
Rapid Detection of Ceftazidime/Avibactam Susceptibility/Resistance in Enterobacterales by Rapid CAZ/AVI NP Test.快速 CAZ/AVI NP 试验检测肠杆菌科中头孢他啶/阿维巴坦的药敏/耐药性。
Emerg Infect Dis. 2024 Feb;30(2):255-261. doi: 10.3201/eid3002.221398.
6
Three lineages causing bloodstream infections variably dominated within a Greek hospital over a 15 year period.在过去的 15 年中，希腊一家医院的血流感染患者中，三种不同的菌属存在不同程度的主导地位。
Microb Genom. 2023 Aug;9(8). doi: 10.1099/mgen.0.001082.
7
Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant -Producing Carrying .携带产头孢他啶-阿维巴坦耐药菌的新生儿血流感染
Antibiotics (Basel). 2023 Aug 5;12(8):1290. doi: 10.3390/antibiotics12081290.
8
Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.新型及重新利用的抗生素在新生儿中用于对抗革兰氏阴性菌的应用。
Antibiotics (Basel). 2023 Jun 19;12(6):1072. doi: 10.3390/antibiotics12061072.
9
Genetic Characterization of Carbapenem-Resistant Clinical Isolates in a Tertiary Hospital in Greece, 2018-2022.2018 - 2022年希腊一家三级医院耐碳青霉烯临床分离株的基因特征分析
Antibiotics (Basel). 2023 May 28;12(6):976. doi: 10.3390/antibiotics12060976.
10
Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.产 KPC-2 肺炎克雷伯菌中由超广谱β-内酰胺酶 VEB-25 引起的对头孢他啶-阿维巴坦的耐药性。
Eur J Clin Microbiol Infect Dis. 2023 May;42(5):639-644. doi: 10.1007/s10096-023-04582-0. Epub 2023 Mar 6.
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
4
Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.希腊医院耐碳青霉烯肺炎克雷伯菌分离株的全国流行病学研究，涉及到帕拉米韦和氨基糖苷类耐药性。
BMC Infect Dis. 2019 Feb 15;19(1):167. doi: 10.1186/s12879-019-3801-1.
5
Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.新型β-内酰胺-β-内酰胺酶抑制剂复方制剂：治疗碳青霉烯类耐药革兰氏阴性病原体的期望。
Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133-149. doi: 10.1080/17425255.2019.1563071. Epub 2019 Jan 10.
6
Epidemiology and resistance phenotypes of carbapenemase-producing in Greece, 2014 to 2016.2014年至2016年希腊产碳青霉烯酶菌的流行病学及耐药表型
Euro Surveill. 2018 Aug;23(31). doi: 10.2807/1560-7917.ES.2018.23.30.1700775.
7
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
8
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.头孢他啶-阿维巴坦与不同抗菌药物联合对产KPC肺炎克雷伯菌临床分离株的体外相互作用
Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.
9
Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.产头孢他啶/阿维巴坦耐药的多重耐药肺炎克雷伯菌的出现。
J Antimicrob Chemother. 2017 Sep 1;72(9):2483-2488. doi: 10.1093/jac/dkx179.
10
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.